United States Tuberculosis Treatment Market Report and Forecast 2025-2034
Description
The United States tuberculosis treatment market was valued at USD 890.40 Million in 2024, driven by the rising tuberculosis incidence and increased focus on multidrug-resistant tuberculosis management in the region. The market is anticipated to grow at a CAGR of 5.10% during the forecast period of 2025-2034, with the values likely to reach USD 1464.24 Million by 2034. The market is driven by the availability of established therapies and government programs supporting treatment access. Advancements in rapid diagnostics and drug formulations offer significant opportunities for improved treatment outcomes and early detection, supporting market growth.
United States Tuberculosis Treatment Market Overview
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially spreading to other organs. Tuberculosis treatment involves a prolonged regimen of antibiotics, typically including isoniazid, rifampin, ethambutol, and pyrazinamide. The United States tuberculosis treatment market is driven by rising public health initiatives, diagnostic advancements, and increased focus on multidrug-resistant tuberculosis management.
United States Tuberculosis Treatment Market Growth Drivers
Rising Tuberculosis Incidence to Accelerate Market Growth in the United States
The increasing incidence of tuberculosis is a significant growth driver in the market. According to the Centers for Disease Control and Prevention (CDC), in March 2023, the country reported 9,633 cases of tuberculosis disease, reflecting a 15.6% rise compared to 2022 and an 8.3% increase from 2019. This highlights the urgent need for enhanced diagnostics, effective treatment regimens, and stronger public health responses, ultimately accelerating the growth of the tuberculosis treatment market in the region.
United States Tuberculosis Treatment Market Trends
Some of the notable trends in the market include the introduction of shorter regimens and advancements in drug-resistant tuberculosis therapies.
Introduction of Shorter Regimens Likely to Boost Market Growth
A notable trend in the market is the growing focus on reducing treatment duration. In March 2024, the Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium launched the CRUSH-TB clinical trial to evaluate new drug combinations aimed at reducing treatment time. This advancement is expected to significantly boost market value and therapeutic adoption.
Advancement in Drug-Resistant Tuberculosis Therapies to Elevate the United States Tuberculosis Treatment Market Value
A rising trend in the market is the advancement of therapies targeting drug-resistant TB. Pharmaceutical research has increasingly focused on novel antimicrobials and improved diagnostics to address multidrug-resistant and extensively drug-resistant tuberculosis. This innovation is enhancing treatment efficacy, improving patient outcomes, and expanding opportunities for market growth.
United States Tuberculosis Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
First-Line Therapy Expected to Dominate the Market Share
First-line therapy and second-line therapy are the types of therapies in the market. First-line therapy is expected to hold a substantial the tuberculosis treatment market due to its effectiveness, lower cost, and widespread use in treating drug-sensitive tuberculosis cases. Medications such as isoniazid and rifampin remain the standard approach for initial treatment. Increasing early diagnosis and adherence to treatment protocols further contribute to the dominance of first-line therapy.
United States Tuberculosis Treatment Market Analysis by Region
The market is primarily driven by the West and South regions. The West, with its advanced healthcare infrastructure and higher immigrant population, shows significant market demand. The South, facing a higher disease burden, also contributes notably to market growth through increased public health initiatives and treatment access. These regions are central to addressing tuberculosis effectively.
Leading Players in the United States Tuberculosis Treatment Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Johnson and Johnson Services Inc.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson is a global healthcare leader actively involved in the market. In July 2024, the company received full approval from the U.S. FDA and the European Commission for Sirturo (bedaquiline), a key treatment for multidrug-resistant tuberculosis and a major advancement in TB care.
Otsuka Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, is actively involved in tuberculosis treatment research. In March 2024, its U.S. affiliate, Otsuka Pharmaceutical, Inc., based in Princeton, New Jersey, announced promising interim Phase 2b/c trial results for Quabodepistat (QBS), a novel compound potentially reducing tuberculosis treatment duration when combined with delamanid and bedaquiline.
GlaxoSmithKline plc
GlaxoSmithKline plc is a major player involved in tuberculosis treatment in the United States. In May 2024, GSK expanded its strategic collaboration with BioVersys to advance alpibectir (BVL-GSK098), a novel anti-tuberculosis drug candidate. This Phase 2a clinical asset targets multidrug-resistant tuberculosis, addressing a critical public health challenge.
Lupin
Lupin Limited, established in 1968 and headquartered in Mumbai, India, is a global pharmaceutical company actively involved in tuberculosis treatment. In September 2021, Lupin partnered with TB Alliance to manufacture and commercialize pretomanid, part of the BPaL regimen for highly drug-resistant tuberculosis. This collaboration aims to enhance access to advanced TB therapies, including in the United States.
Other key players in the market include Sanofi, Pfizer Inc., Novartis AG, Merck & Co., Inc., Cipla Ltd., and Macleods Pharmaceuticals Ltd.
Key Questions Answered in the United States Tuberculosis Treatment Market Report
United States Tuberculosis Treatment Market Overview
Tuberculosis is a contagious bacterial infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but potentially spreading to other organs. Tuberculosis treatment involves a prolonged regimen of antibiotics, typically including isoniazid, rifampin, ethambutol, and pyrazinamide. The United States tuberculosis treatment market is driven by rising public health initiatives, diagnostic advancements, and increased focus on multidrug-resistant tuberculosis management.
United States Tuberculosis Treatment Market Growth Drivers
Rising Tuberculosis Incidence to Accelerate Market Growth in the United States
The increasing incidence of tuberculosis is a significant growth driver in the market. According to the Centers for Disease Control and Prevention (CDC), in March 2023, the country reported 9,633 cases of tuberculosis disease, reflecting a 15.6% rise compared to 2022 and an 8.3% increase from 2019. This highlights the urgent need for enhanced diagnostics, effective treatment regimens, and stronger public health responses, ultimately accelerating the growth of the tuberculosis treatment market in the region.
United States Tuberculosis Treatment Market Trends
Some of the notable trends in the market include the introduction of shorter regimens and advancements in drug-resistant tuberculosis therapies.
Introduction of Shorter Regimens Likely to Boost Market Growth
A notable trend in the market is the growing focus on reducing treatment duration. In March 2024, the Centers for Disease Control and Prevention’s Tuberculosis Trials Consortium launched the CRUSH-TB clinical trial to evaluate new drug combinations aimed at reducing treatment time. This advancement is expected to significantly boost market value and therapeutic adoption.
Advancement in Drug-Resistant Tuberculosis Therapies to Elevate the United States Tuberculosis Treatment Market Value
A rising trend in the market is the advancement of therapies targeting drug-resistant TB. Pharmaceutical research has increasingly focused on novel antimicrobials and improved diagnostics to address multidrug-resistant and extensively drug-resistant tuberculosis. This innovation is enhancing treatment efficacy, improving patient outcomes, and expanding opportunities for market growth.
United States Tuberculosis Treatment Market Segmentation
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Disease Type
- Active TB
- Latent TB
- First-Line Therapy
- Second-Line Therapy
- Tablets
- Capsules
- Injections
- Others
- Oral
- Parenteral
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
First-Line Therapy Expected to Dominate the Market Share
First-line therapy and second-line therapy are the types of therapies in the market. First-line therapy is expected to hold a substantial the tuberculosis treatment market due to its effectiveness, lower cost, and widespread use in treating drug-sensitive tuberculosis cases. Medications such as isoniazid and rifampin remain the standard approach for initial treatment. Increasing early diagnosis and adherence to treatment protocols further contribute to the dominance of first-line therapy.
United States Tuberculosis Treatment Market Analysis by Region
The market is primarily driven by the West and South regions. The West, with its advanced healthcare infrastructure and higher immigrant population, shows significant market demand. The South, facing a higher disease burden, also contributes notably to market growth through increased public health initiatives and treatment access. These regions are central to addressing tuberculosis effectively.
Leading Players in the United States Tuberculosis Treatment Market
The key features of the market report comprise patent analysis, grant analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Johnson and Johnson Services Inc.
Established in 1886 and headquartered in New Brunswick, New Jersey, Johnson & Johnson is a global healthcare leader actively involved in the market. In July 2024, the company received full approval from the U.S. FDA and the European Commission for Sirturo (bedaquiline), a key treatment for multidrug-resistant tuberculosis and a major advancement in TB care.
Otsuka Pharmaceutical, Inc.
Otsuka Pharmaceutical Co., Ltd., headquartered in Tokyo, Japan, is actively involved in tuberculosis treatment research. In March 2024, its U.S. affiliate, Otsuka Pharmaceutical, Inc., based in Princeton, New Jersey, announced promising interim Phase 2b/c trial results for Quabodepistat (QBS), a novel compound potentially reducing tuberculosis treatment duration when combined with delamanid and bedaquiline.
GlaxoSmithKline plc
GlaxoSmithKline plc is a major player involved in tuberculosis treatment in the United States. In May 2024, GSK expanded its strategic collaboration with BioVersys to advance alpibectir (BVL-GSK098), a novel anti-tuberculosis drug candidate. This Phase 2a clinical asset targets multidrug-resistant tuberculosis, addressing a critical public health challenge.
Lupin
Lupin Limited, established in 1968 and headquartered in Mumbai, India, is a global pharmaceutical company actively involved in tuberculosis treatment. In September 2021, Lupin partnered with TB Alliance to manufacture and commercialize pretomanid, part of the BPaL regimen for highly drug-resistant tuberculosis. This collaboration aims to enhance access to advanced TB therapies, including in the United States.
Other key players in the market include Sanofi, Pfizer Inc., Novartis AG, Merck & Co., Inc., Cipla Ltd., and Macleods Pharmaceuticals Ltd.
Key Questions Answered in the United States Tuberculosis Treatment Market Report
- What was the United States tuberculosis treatment market value in 2024?
- What is the United States tuberculosis treatment market forecast outlook for 2025-2034?
- What is the market segmentation based on disease type?
- What is the market breakup based on the therapy?
- What is the market breakup based on the dosage form?
- How is the market segmented based on route of administration?
- How is the market divided based on the end user?
- What are the major factors aiding the United States tuberculosis treatment market demand?
- How has the market performed so far, and how is it anticipated to perform in the coming years?
- What are the market's major drivers, opportunities, and restraints?
- What are the major United States tuberculosis treatment market trends?
- Which disease type is expected to dominate the market segment?
- Which therapy is expected to dominate the market segment?
- Which dosage form is projected to lead the market segment?
- Which route of administration is anticipated to drive the market segment?
- Which end user is likely to dominate the market segment?
- Who are the key players involved in the United States tuberculosis treatment market?
- What is the patent landscape of the market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Tuberculosis Treatment Market Overview- United States
- 3.1 Tuberculosis Treatment Market Historical Value (2018-2024)
- 3.2 Tuberculosis Treatment Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Tuberculosis Treatment Market: Disease Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Tuberculosis Treatment Market - Epidemiology Scenario and Forecast – United States
- 7.1 United States Epidemiology Scenario Overview (2018-2034)
- 7.2 Prevalence, by Country
- 7.3 Diagnosed Cases, by Country
- 7.4 Treatment Seeking Rate, by Country
- 8 Tuberculosis Treatment Market Landscape – 8 Major Markets
- 8.1 Tuberculosis Treatment Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Tuberculosis Treatment Market: Product Landscape
- 8.2.1 Analysis by Disease Type
- 8.2.2 Analysis by Therapy
- 8.2.3 Analysis by Route of Administration
- 8.2.4 Analysis by Dosage Form
- 9 Clinical Trials and Pipeline Analysis
- 9.1 Analysis by Trial Registration Year
- 9.2 Analysis by Trial Status
- 9.3 Analysis by Trial Phase
- 9.4 Analysis by Therapeutic Area
- 9.5 Analysis by Geography
- 9.6 Drug Pipeline Analysis
- 10 Tuberculosis Treatment Market Challenges and Unmet Needs
- 10.1 Treatment Pathway Challenges
- 10.2 Compliance and Drop-Out Analysis
- 10.3 Awareness and Prevention Gaps
- 11 Cost of Treatment
- 12 Tuberculosis Treatment Market Dynamics
- 12.1 Market Drivers and Constraints
- 12.2 SWOT Analysis
- 12.2.1 Strengths
- 12.2.2 Weaknesses
- 12.2.3 Opportunities
- 12.2.4 Threats
- 12.3 PESTEL Analysis
- 12.3.1 Political
- 12.3.2 Economic
- 12.3.3 Social
- 12.3.4 Technological
- 12.3.5 Legal
- 12.3.6 Environment
- 12.4 Porter’s Five Forces Model
- 12.4.1 Bargaining Power of Suppliers
- 12.4.2 Bargaining Power of Buyers
- 12.4.3 Threat of New Entrants
- 12.4.4 Threat of Substitutes
- 12.4.5 Degree of Rivalry
- 12.5 Key Demand Indicators
- 12.6 Key Price Indicators
- 12.7 Industry Events, Initiatives, and Trends
- 12.8 Value Chain Analysis
- 13 United States Tuberculosis Treatment Market (218-2034)
- 13.1 United States Tuberculosis Treatment Market (2018-2034) by Disease Type
- 13.1.1 Market Overview
- 13.1.2 Active TB
- 13.1.3 Latent TB
- 13.2 United States Tuberculosis Treatment Market (2018-2034) by Therapy
- 13.2.1 Market Overview
- 13.2.2 First-Line Therapy
- 13.2.3 Second-Line Therapy
- 13.3 United States Tuberculosis Treatment Market (2018-2034) by Dosage Form
- 13.3.1 Market Overview
- 13.3.2 Tablets
- 13.3.3 Capsules
- 13.3.4 Injections
- 13.3.5 Others
- 13.4 United States Tuberculosis Treatment Market (2018-2034) by Route of Administration
- 13.4.1 Market Overview
- 13.4.2 Oral
- 13.4.3 Parenteral
- 13.4.4 Others
- 13.5 United States Tuberculosis Treatment Market (2018-2034) by End User
- 13.5.1 Market Overview
- 13.5.2 Hospital Pharmacies
- 13.5.3 Retail Pharmacies
- 13.5.4 Online Pharmacies
- 13.5.5 Others
- 14 Regulatory Framework
- 15 Patent Analysis
- 15.1 Analysis by Type of Patent
- 15.2 Analysis by Publication Year
- 15.3 Analysis by Issuing Authority
- 15.4 Analysis by Patent Age
- 15.5 Analysis by CPC Analysis
- 15.6 Analysis by Patent Valuation
- 16 Grants Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Application
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by NIH Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Drug Class of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Drug Class of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis (Top 5 Companies)
- 19.2 Sanofi
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Development
- 19.2.5 Certifications
- 19.3 Pfizer Inc.
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Development
- 19.3.5 Certifications
- 19.4 Johnson and Johnson Services Inc.
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Development
- 19.4.5 Certifications
- 19.5 Otsuka Pharmaceutical, Inc
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Development
- 19.5.5 Certifications
- 19.6 Novartis AG
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Development
- 19.6.5 Certifications
- 19.7 GlaxoSmithKline plc
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Development
- 19.7.5 Certifications
- 19.8 Merck & Co., Inc.
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Development
- 19.8.5 Certifications
- 19.9 Lupin
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Development
- 19.9.5 Certifications
- 19.10 Cipla Ltd.
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Development
- 19.10.5 Certifications
- 19.11 Macleods Pharmaceuticals Ltd.
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Company News and Development
- 19.11.5 Certifications
- 20 Tuberculosis Treatment Market - Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
